Watch these two videos. Katz is willing to give priority review and also accept a drug that has risk if efficacy is strong.
3. The Progress of Drug Development. A group discussion at the 2008 ICAD conference in Chicago, moderated by Maria Carillo of the Alzheimer's Association. Features Paul Aisen, UCSC/ADCS; Richard Frank, GE Healthcare, Russell Katz, FDA; Marcelle Morrison-Bogorad, NIA; Lennart Mucke, UCSF/Gladstone Institute, Dale Schenk, Elan Pharmaceuticals; Eric Siemers, Eli Lilly and Company
4. Approving Drugs for Alzheimer's. A conversation with Russell Katz, FDA